AbGn-168H Neihulizumab




Disease Population

In the U.S., 5,483 patients/year develop acute GvHD following an allogeneic HCT[1].
Trial Description
Study evaluating the safety, signs of efficacy, pharmacokinetics, receptor occupancy and pharmacodynamics biomarkers of Neihulizumab in patients with steroid-refractory acute GvHD
Trial Center
Duarte, CA City of Hope
  • Duarte, California, United States, 91010
  • Roxanne Garcia/Kay Chanea
  • 626-218-2340 ext 62340
Atlanta, GA Emory University
  • Atlanta, Georgia, United States, 30322
  • Shantoria Brown
  • 404-778-6547
Chicago, IL University of Chicago
  • Chicago, Illinois, United States, 60637
  • Michael Gomez
  • 773-834-5314
Ann Arbor, MI University of Michigan
  • Ann Arbor, Michigan, United States, 48109
  • Maggie Kennel
  • 734-232-6816
Minneapolis, MN University of Minnesota
  • Minneapolis, Minnesota, United States, 55455
  • Janine Delage
  • 612-625-8341
Nashville, TN Vanderbilt-Ingram Cancer Center
  • Nashville, Tennessee, United States, 37232
  • Delia Darst
  • 615-343-7190
Seattle, WA Fred Hutchinson
  • Seattle, Washington, United States, 98109
  • Anise Marshall
Milwaukee, WI Medical College of Wisconsin
  • Milwaukee, Wisconsin, United States, 53226
  • Kaylee Meisinger
  • 414-805-8926
About SR-aGvHD
Graft-versus-host disease (GvHD) is a multisystem disorder that occurs after an allogeneic hematopoietic cell transplant (HCT) when immune cells (T cells) from the donor (the graft) recognize the transplant recipient (the host) as foreign, initiating an immune reaction that causes disease in the transplant recipient.

Allogeneic hematopoietic cell transplantation is a common treatment for many different cancers, particularly relapse of hematological malignancies (such as leukemia or lymphoma), as well as some other (non-cancer) conditions that affect the blood or immune system. In addition to HCT procedures, GvHD can also occur after transplantation of solid organs that may contain immune cells such as T cells.

GvHD is a significant cause of medical problems and death following an allogeneic HCT. Somewhere between 30 and 70 percent of transplant recipients develop acute GvHD, depending on donor type, transplant technique and other factors.

GvHD primarily affects the skin, the liver and the gastrointestinal tract. Some people have a very mild form, which doesn’t last long. For others, GvHD can be severe, and in some cases, may even be life threatening. Some people may have GvHD over many years, or even a lifetime.
1. IQVIA US market survey with data to 2016
Details about AltruBio Clinical Trial can be found at